Assessing Jazz Pharmaceuticals: Insights From 7 Financial Analysts
Assessing Jazz Pharmaceuticals: Insights From 7 Financial Analysts
評估爵士製藥：來自7位金融分析師的見解
In the last three months, 7 analysts have published ratings on Jazz Pharmaceuticals (NASDAQ:JAZZ), offering a diverse range of perspectives from bullish to bearish.
過去三個月，有7位分析師對Jazz Pharmaceuticals（納斯達克股票代碼：JAZZ）發表了評級，提供了從看好到看淡的多種觀點。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
總結他們最近的評估，下表展示了過去30天內不斷變化的情緒，並將其與之前的幾個月進行了比較。
In the assessment of 12-month price targets, analysts unveil insights for Jazz Pharmaceuticals, presenting an average target of $184.86, a high estimate of $222.00, and a low estimate of $113.00. Experiencing a 6.73% decline, the current average is now lower than the previous average price target of $198.20.
在12個月的價格預測中，分析師爲爵士製藥提供了洞察，展示了平均目標爲184.86美元，最高估值爲222.00美元，最低估值爲113.00美元。目前平均價格目標下降了6.73％，現在低於之前的平均價格目標198.20美元。
Deciphering Analyst Ratings: An In-Depth Analysis
分析師評級解讀：深入分析
A clear picture of...
通過分析...
登入免費觀看全文
登入/註冊